$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000142545020000107 Filed on August 06, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$13.59M	$18.20M
YoY Change	-25.31%	20.71%
Cost Of Revenue	$3.532M	$4.581M
YoY Change	-22.9%	20.33%
Gross Profit	$10.06M	$13.62M
YoY Change	-26.13%	20.84%
Gross Profit Margin	74.02%	74.83%
Selling, General & Admin	$16.20M	$14.18M
YoY Change	14.26%	15.48%
% of Gross Profit	160.99%	104.08%
Research & Development	$881.0K	$1.234M
YoY Change	-28.61%	10.67%
% of Gross Profit	8.76%	9.06%
Depreciation & Amortization	$1.910M	$1.080M
YoY Change	76.85%	50.0%
% of Gross Profit	18.98%	7.93%
Operating Expenses	$17.08M	$15.41M
YoY Change	10.83%	15.08%
Operating Profit	-$7.017M	-$1.790M
YoY Change	292.01%	-15.57%
Interest Expense	-$2.310M	-$630.0K
YoY Change	266.67%	12.5%
% of Operating Profit
Other Income/Expense, Net	-$2.430M	-$669.0K
YoY Change	263.23%	16.96%
Pretax Income	-$9.447M	-$2.459M
YoY Change	284.18%	-8.59%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.447M	-$2.618M
YoY Change	260.85%	-2.75%
Net Earnings / Revenue	-69.5%	-14.38%
Basic Earnings Per Share	-$0.54
Diluted Earnings Per Share	-$0.54	-$181.3K
COMMON SHARES
Basic Shares Outstanding	17.55M shares	14.68M shares
Diluted Shares Outstanding	17.55M shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$113.1M	$21.90M
YoY Change	416.44%	-17.36%
Cash & Equivalents	$113.1M	$21.86M
Short-Term Investments
Other Short-Term Assets	$2.900M	$36.70M
YoY Change	-92.1%	3236.36%
Inventory	$48.88M	$32.86M
Prepaid Expenses
Receivables	$14.90M	$14.97M
Other Receivables	$700.0K	$500.0K
Total Short-Term Assets	$180.4M	$106.8M
YoY Change	68.82%	70.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.13M	$20.92M
YoY Change	15.38%	63.78%
Goodwill	$68.42M	$10.97M
YoY Change	523.64%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$148.1M	$23.67M
YoY Change	525.64%	56.68%
TOTAL ASSETS
Total Short-Term Assets	$180.4M	$106.8M
Total Long-Term Assets	$148.1M	$23.67M
Total Assets	$328.5M	$151.4M
YoY Change	116.92%	94.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.003M	$6.000M
YoY Change	0.05%	9.99%
Accrued Expenses	$4.500M	$4.000M
YoY Change	12.5%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$30.00M
YoY Change	-100.0%
Long-Term Debt Due	$128.0K	$30.12M
YoY Change	-99.58%	26092.17%
Total Short-Term Liabilities	$24.77M	$42.19M
YoY Change	-41.28%	302.16%
LONG-TERM LIABILITIES
Long-Term Debt	$21.02M	$21.11M
YoY Change	-0.45%	-16.55%
Other Long-Term Liabilities	$120.0K	$100.0K
YoY Change	20.0%
Total Long-Term Liabilities	$61.26M	$21.16M
YoY Change	189.46%	-16.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.77M	$42.19M
Total Long-Term Liabilities	$61.26M	$21.16M
Total Liabilities	$86.03M	$63.35M
YoY Change	35.8%	77.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.2M	-$120.7M
YoY Change	18.62%	9.0%
Common Stock	$5.000K	$4.000K
YoY Change	25.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$242.5M	$88.08M
YoY Change
Total Liabilities & Shareholders Equity	$328.5M	$151.4M
YoY Change	116.92%	94.53%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$9.447M	-$2.618M
YoY Change	260.85%	-2.75%
Depreciation, Depletion And Amortization	$1.910M	$1.080M
YoY Change	76.85%	50.0%
Cash From Operating Activities	-$7.750M	-$6.940M
YoY Change	11.67%	4.52%
INVESTING ACTIVITIES
Capital Expenditures	-$2.010M	-$3.700M
YoY Change	-45.68%	160.56%
Acquisitions
YoY Change
Other Investing Activities	-$1.720M	-$49.97M
YoY Change	-96.56%
Cash From Investing Activities	-$3.730M	-$53.68M
YoY Change	-93.05%	3680.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.96M	30.06M
YoY Change	136.06%	-100300.0%
NET CHANGE
Cash From Operating Activities	-7.750M	-6.940M
Cash From Investing Activities	-3.730M	-53.68M
Cash From Financing Activities	70.96M	30.06M
Net Change In Cash	59.48M	-30.56M
YoY Change	-294.63%	277.75%
FREE CASH FLOW
Cash From Operating Activities	-$7.750M	-$6.940M
Capital Expenditures	-$2.010M	-$3.700M
Free Cash Flow	-$5.740M	-$3.240M
YoY Change	77.16%	-37.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	kids	Class Of Warrant Or Right Term ClassOfWarrantOrRightTerm	P10Y
	dei	Document Type DocumentType	10-Q
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19549201	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113054000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70777000	USD
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1361000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	185000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	506000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14897000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16003000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	48875000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	38000000	USD
CY2020Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	656000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	564000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1534000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1464000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	180377000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	128058000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24131000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21349000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42206000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14484000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	68420000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	13773000	USD
CY2020Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	13357000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4490000	USD
CY2020Q2	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	123983000	USD
CY2019Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	32747000	USD
CY2020Q2	us-gaap	Assets Assets	328491000	USD
CY2019Q4	us-gaap	Assets Assets	182154000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6003000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6467000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4501000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4349000	USD
CY2020Q2	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	128000	USD
CY2019Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	124000	USD
CY2020Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	11485000	USD
CY2019Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	0	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2654000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2723000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24771000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13663000	USD
CY2020Q2	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21017000	USD
CY2019Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	26067000	USD
CY2020Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	12021000	USD
CY2019Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	0	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28100000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	63000	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	61258000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	26130000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	86029000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	39793000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19544008	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19544008	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16723128	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16723128	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32856000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3532000	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385510000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271182000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143214000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128822000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	242462000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	142361000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	328491000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	182154000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18200000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4581000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7675000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8582000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	10061000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	13619000	USD
	us-gaap	Gross Profit GrossProfit	22274000	USD
	us-gaap	Gross Profit GrossProfit	24274000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5620000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7606000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13184000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14153000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10577000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6569000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18458000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12181000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	881000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1234000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2146000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2447000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	17078000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	15409000	USD
	us-gaap	Operating Expenses OperatingExpenses	33788000	USD
	us-gaap	Operating Expenses OperatingExpenses	28781000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7017000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1790000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11514000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4507000	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1399000	USD
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-632000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1778000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-935000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9447000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2459000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-121000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-190000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2430000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-669000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2878000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-972000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14392000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5479000	USD
CY2020Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2019Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-159000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-159000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9447000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14392000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5638000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17549118	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14451979	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16986485	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14409752	shares
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5638000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1522000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-133000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	164000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	168000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1522000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-133000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	164000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	168000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7925000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2751000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14228000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5470000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	142361000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4945000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1358000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	958000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1750000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	187000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	139267000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1522000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	593000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2495000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	37638000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70394000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	242462000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	565000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	471000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-133000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10000000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	692000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	88082000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5638000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3285000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1912000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3453000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1163000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	886000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	0	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-1609000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	5499000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-139000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14707000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10785000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9599000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5139000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-66000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-746000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1934000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-129000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	50000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	371000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14707000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10414000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	170000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5160000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8514000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9349000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-58610000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-47000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9349000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58657000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	30000000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70207000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1281000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	657000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	61000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	59000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66427000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30598000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42388000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38473000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	72027000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	60691000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	114415000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	22218000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	360000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114415000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21858000	USD
	us-gaap	Interest Paid Net InterestPaidNet	513000	USD
	us-gaap	Interest Paid Net InterestPaidNet	935000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	229000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	267000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143214000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128822000	USD
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div style="padding-right:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard, Pediatric Nailing Platform \| Femur, Orthex, QuickPack</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">TM </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">and ApiFix to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand, permitting us to sell under an agency model direct to local hospitals in these countries. In September 2018, we further expanded operations in Canada selling direct to local hospitals, and in January 2019 we expanded to Belgium and the Netherlands. Additionally, in March 2019 we established a holding company and an operating company in the Netherlands and began selling direct to Italy in March 2020 enhancing our operations in Europe. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 4, 2019, we purchased all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. ("Vilex") and all the issued and outstanding units of membership interests in Orthex, LLC ("Orthex") for $60,000 in total consideration. Vilex and Orthex (the "Vilex Companies") are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as Orthex Hexapod technology which is used to treat pediatrics congenital deformities and limb length discrepancies.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2019, we divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron Capital LLC ("Squadron") in exchange for a $25,000 reduction in a Term Note owed to Squadron in connection with the initial acquisition. As part of the sale, we also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property and a mutual distribution agreement. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 9, 2020, we purchased all the issued and outstanding membership interest of Telos Partners, LLC ("Telos") for $3,300 in total consideration. Telos is a boutique regulatory consulting firm formed in Colorado. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 1, 2020, we purchased all the issued and outstanding membership interest of ApiFix, Ltd. ("ApiFix") for (a) $2,000 in cash, and (b) 934,783 shares of the Company's common stock, $0.00025 par value per share, representing approximately $35,000 (based on a closing share price of $37.63 on April 1, 2020. ApiFix, a corporation organized under the laws of Israel, has developed a minimally invasive deformity correction system for patients with Adolescent Idiopathic Scoliosis ("ApiFix System"). In addition, we have also agreed to pay as part of the purchase price the following anniversary payments: (i) $13,000 on the second anniversary of the closing date, provided that such payment will be paid earlier if 150 clinical procedures using the ApiFix System are completed in the United States before such anniversary date, (ii) $8,000 on the third anniversary of the closing date; and (iii) $9,000 on the fourth anniversary of the closing date. In addition, to the extent that the product of our revenues from the ApiFix System for the twelve months ended June 30, 2024 multiplied by 2.25 exceeds the anniversary payments </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">actually made for the third and fourth years, we have agreed to pay the selling shareholders a system sales payment in the amount of such excess. The anniversary payments and system sales payment may each be made in cash or cash and common stock. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 10, 2020, we purchased certain intellectual property assets from Band-Lok, LLC, a North Carolina limited liability company ("Band-Lok"), related to its Tether Clamp and Implantation System ("Tether Clamp System") for approximately $3,400 in total consideration. We use the Tether Clamp System in connection with our Bandloc 5.5/6.0 System. We were previously the sole licensee of the purchased assets under a license agreement with Band-Lok. </span></div>Our largest investor is Squadron, a private investment firm based in Granby, Connecticut.
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. The impact of the coronavirus disease ("COVID-19") has significantly increased economic and demand uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	87379000	USD
CY2019Q2	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	40.76
CY2019Q2	kids	Business Combination Escrow Deposit Maximum Term BusinessCombinationEscrowDepositMaximumTerm	P20M
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	737000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	13773000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	68420000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	44897000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2691000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42206000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16072000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1588000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14484000	USD
CY2020Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	21145000	USD
CY2019Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	26191000	USD
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	128000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	124000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21017000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26067000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	1062000	USD
CY2019Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	260000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation	16200000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subject To Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease	22430000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	70628	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.97
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y2M12D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41370	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	30.97
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29258	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.97
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y2M12D
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2495000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	692000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3453000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1163000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	404	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	404	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2020Q2	kids	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9447000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2618000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14392000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5638000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17549118	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14451979	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16986485	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14409752	shares
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	123000	USD
	kids	Research And Development Arrangement Contract To Perform For Others Minimum Annual Royalty Payment ResearchAndDevelopmentArrangementContractToPerformForOthersMinimumAnnualRoyaltyPayment	500000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	467009	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403011	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18200000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32856000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18200000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32856000	USD
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	120000	USD

Files In Submission

Name	View Source	Status
0001425450-20-000107-index-headers.html	Edgar Link	pending
0001425450-20-000107-index.html	Edgar Link	pending
0001425450-20-000107.txt	Edgar Link	pending
0001425450-20-000107-xbrl.zip	Edgar Link	pending
exhibit311-ceocertific.htm	Edgar Link	pending
exhibit312-cfocertific.htm	Edgar Link	pending
exhibit321-ceocertific.htm	Edgar Link	pending
exhibit322-cfocertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20200630.htm	Edgar Link	pending
kids-20200630.xsd	Edgar Link	pending
kids-20200630_cal.xml	Edgar Link	unprocessable
kids-20200630_def.xml	Edgar Link	unprocessable
kids-20200630_htm.xml	Edgar Link	completed
kids-20200630_lab.xml	Edgar Link	unprocessable
kids-20200630_pre.xml	Edgar Link	unprocessable
kids10-qex103xsecondam.htm	Edgar Link	pending
kids10-qex104xfirstame.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2020 Q2 Form 10-Q Financial Statement

#000142545020000107 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2020 Q2 Form 10-Q Financial Statement

#000142545020000107 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids